Immix Biopharma (IMMX) Total Liabilities (2020 - 2026)

Immix Biopharma has disclosed Total Liabilities across 7 years of filings, most recently posting $11.5 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $11.5 million, up 11.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.5 million (up 11.2% YoY), and the FY2025 annual result was $11.0 million, up 13.9% from the prior year.
• Total Liabilities came in at $11.5 million for Q1 2026 at Immix Biopharma, up from $11.0 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $11.8 million in Q3 2025 to a low of $365086.0 in Q1 2022.
• The 5-year median for Total Liabilities is $4.9 million (2024), against an average of $5.8 million.
• Peak annual rise in Total Liabilities reached 765.33% in 2022, while the deepest fall reached 93.61% in 2022.
• Immix Biopharma's Total Liabilities stood at $1.7 million in 2022, then jumped by 112.88% to $3.7 million in 2023, then soared by 160.54% to $9.7 million in 2024, then grew by 13.9% to $11.0 million in 2025, then gained by 3.69% to $11.5 million in 2026.
• The last three Total Liabilities figures came in at $11.5 million (Q1 2026), $11.0 million (Q4 2025), and $11.8 million (Q3 2025), per Business Quant data.